drugset
drugset / Trial / NCT04080882

Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Platysmal Bands

NCT04080882 ↗

Phase 2 Completed 80 enrolled Galderma R&D
RandomizedSequentialDouble-blindTreatment

Summary

Interventional phase 2 study to evaluate safety and efficacy of abobotulinumtoxinA for the treatment of platysmal bands.

Timeline

Start
2019-09-25
Primary completion
2019-12-30
Completion
2020-06-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic — Other

Indications

No indication recorded.